O
ARRY

OrbiMed’s Array Biopharma Inc ARRY Stock Holding History

OrbiMed’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,806,900
Closed -$73.1M – 161
2018
Q3 		$73.1M Sell
4,806,900
-94,000
-2% -$1.44M 0.88% 34
2018
Q2 		$82.2M Hold
4,900,900
– – 0.98% 34
2018
Q1 		$80M Sell
4,900,900
-2,720,500
-36% -$43.6M 0.99% 34
2017
Q4 		$97.6M Sell
7,621,400
-6,561,500
-46% -$74.6M 1.23% 24
2017
Q3 		$174M Hold
14,182,900
– – 1.67% 19
2017
Q2 		$119M Hold
14,182,900
– – 1.24% 24
2017
Q1 		$127M Sell
14,182,900
-1,905,900
-12% -$20.3M 1.44% 21
2016
Q4 		$141M Buy
16,088,800
+1,908,900
+13% +$14M 1.8% 19
2016
Q3 		$95.7M Buy
14,179,900
+3,206,000
+29% +$12.4M 1.09% 32
2016
Q2 		$39.1M Buy
10,973,900
+284,900
+3% +$928K 0.41% 58
2016
Q1 		$31.5M Hold
10,689,000
– – 0.33% 58
2015
Q4 		$45.1M Buy
10,689,000
+628,500
+6% +$2.87M 0.41% 55
2015
Q3 		$45.9M Hold
10,060,500
– – 0.46% 47
2015
Q2 		$72.5M Buy
10,060,500
+828,190
+9% +$6.11M 0.61% 48
2015
Q1 		$68M Buy
9,232,310
+1,984,610
+27% +$14.1M 0.58% 47
2014
Q4 		$34.3M Buy
7,247,700
+844,900
+13% +$3.34M 0.33% 63
2014
Q3 		$22.9M Hold
6,402,800
– – 0.24% 70
2014
Q2 		$29.2M Buy
6,402,800
+105,800
+2% +$438K 0.34% 55
2014
Q1 		$29.6M Buy
6,297,000
+972,000
+18% +$4.89M 0.36% 51
2013
Q4 		$26.7M Buy
5,325,000
+493,400
+10% +$2.69M 0.39% 55
2013
Q3 		$30.1M Sell
4,831,600
-33,400
-0.7% -$198K 0.54% 44
2013
Q2 		$22.1M Buy
+4,865,000
New +$26.2M 0.47% 43

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OrbiMed's ARRY Position: Q4 2018 in Review

OrbiMed sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 4,806,900 shares — an estimated $73.1M sold.

OrbiMed first reported a position in ARRY in Q2 2013 and held it in 22 quarters. The position peaked at $174M in Q3 2017. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

  • OrbiMed reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
  • OrbiMed sold 4,806,900 Array Biopharma Inc shares in Q4 2018, an estimated $73.1M.
  • OrbiMed first reported a position in Array Biopharma Inc in Q2 2013 and held it in 22 quarters.
  • OrbiMed's Array Biopharma Inc position peaked at $174M in Q3 2017.
  • 236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.